ℹ️ Observational Association Only Evidence
Researchers analyzed whole-genome sequencing data from 985,026 participants across Genomics England, UK Biobank, and the All of Us Research Program to characterize pathogenic DMPK CTG repeat expansions underlying myotonic dystrophy type 1 (DM1). Pathogenic expansions were identified in 645 individuals, approximately 1 in 1,527, a frequency higher than historical clinically ascertained prevalence estimates. Linked health records also associated pathogenic expansions with cardiac disease, particularly conduction abnormalities, while most expansion carriers had no previous DM1 diagnosis.
Clinical Considerations
- Pathogenic DMPK expansions occurred in 0.07% of participants, compared with historical DM1 prevalence estimates of approximately 1 in 3,000 to 8,000.
- Expansions appeared across ancestry groups, although most identified carriers were of European ancestry.
- In UK Biobank, pathogenic expansions were associated with approximately twice the odds of any cardiac diagnosis (OR, 2.06; 95% CI, 1.58-2.67).
- The strongest cardiac association involved conduction abnormalities, including atrioventricular and left bundle-branch block, atrial fibrillation, and flutter (OR, 4.86; 95% CI, 3.38-6.79).
- Approximately 1 in 10 expansion carriers had a cataract diagnosis before age 55.
- Most individuals carrying a pathogenic expansion lacked a previous DM1 diagnosis, although identifying a genetic expansion within population sequencing data does not by itself characterize an individual’s clinical expression or disease trajectory.
Practice Applications
- Recognize that population genomic data may identify substantially more pathogenic DMPK expansions than traditional clinically ascertained prevalence estimates suggest.
- Consider DM1 within the differential when compatible neuromuscular findings occur alongside characteristic cardiac conduction disease or early-onset cataracts.
- Interpret population expansion frequency separately from clinically manifest disease prevalence, particularly given DM1’s variable phenotype.
- Integrate genetic findings with neurologic, cardiac, ophthalmic, and family-history assessment rather than treating sequencing results as standalone clinical characterization.
- Monitor further evidence defining penetrance, ancestry-specific prevalence, and outcomes among individuals identified through population-scale genomic screening.
PATIENT EDUCATION
OBESITY/WEIGHT MANAGEMENT
EXERCISE/TRAINING
LEGAL MATTERS
GUIDELINES/RECOMMENDATIONS